Emmessar Biotech & Nutrition Ltd
Emmessar Biotech & Nutrition Ltd. engages in the manufacture and marketing of healthcare and nutritional products. The company is headquartered in Mumbai, Maharashtra. Its segments include Healthcare and Rent on Leasehold Land. Its product category includes Bone Care, General Health, Muscle Care, Pain Relief, Sexual Health, Skin Care and Skin Cure. Its products include CalmCream, CalmCream RESQ, Cute-N-Comely Cream, Frejomus Capsules, MagiCream, MSM Powder, PsoriBalm, Sepecer Capsules, Supportt-Bones Powder, and Supportt-Joint Powder. Its Skin Cure products include Acnea Gel, BanDruff Cream, Dermat Ointment, Fungi-Rid Capsules, Fungi-Rid Cream, Perfect Skin Syrup, PsoriBalm, Dermat Ointment and others. Its general health products include BioSulf Powder, CC-99 Cough Syrup, Diabeteze Capsules, Frejomus Capsules, Gud-Hart Capsules, and others. Its Muscle Care products include Muscle Flex Capsules and Muscle Flex Gel. Its Pain Relief products include Supportt-Joint Powder and Vedarin Balm.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Emmessar Biotech & Nutrition Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (—).
- Piotroski financial solvency score: 5/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | — | — | — |
| Profit | — | — | — |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.